Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06382649
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-04-19
Brief Title:
Rivastigmine for Antimuscarinic Delirium
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Rivastigmine for Antimuscarinic Delirium a Randomized Placebo-controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIVA-AM
Brief Summary:
Antimuscarinic delirium AMD is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors Physostigmine the standard antidote for AMD currently has very limited availability in the United States due to an interruption of production
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care In order to investigate the effectiveness of rivastigmine the investigators propose a randomized placebo-controlled clinical trial of rivastigmine for AMD The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care In order to investigate the effectiveness of rivastigmine the investigators propose a randomized placebo-controlled clinical trial of rivastigmine for AMD The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None